Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: substudy of the RE-LY trial

In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain.We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Douketis, James D. (VerfasserIn) , Brückmann, Martina (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2015: 113/3 (Mar)
In: Thrombosis and haemostasis
Year: 2015, Jahrgang: 113, Heft: 3, Pages: 625-632
ISSN:2567-689X
DOI:10.1160/TH14-04-0305
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1160/TH14-04-0305
Verlag, Volltext: https://th-schattauer-de.ezproxy.medma.uni-heidelberg.de/contents/archive/issue/2189/manuscript/23790.html
Volltext
Verfasserangaben:J.D. Douketis, J.S. Healey, M. Brueckmann, J.W. Eikelboom, M.D. Ezekowitz, M. Fraessdorf, H. Noack, J. Oldgren, P. Reilly, A.C. Spyropoulos, L. Wallentin, S.J. Connolly

MARC

LEADER 00000caa a2200000 c 4500
001 1563887479
003 DE-627
005 20220813232019.0
007 cr uuu---uuuuu
008 170928s2015 xx |||||o 00| ||eng c
024 7 |a 10.1160/TH14-04-0305  |2 doi 
035 |a (DE-627)1563887479 
035 |a (DE-576)493887474 
035 |a (DE-599)BSZ493887474 
035 |a (OCoLC)1340979770 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Douketis, James D.  |e VerfasserIn  |0 (DE-588)1140590731  |0 (DE-627)898575745  |0 (DE-576)493887091  |4 aut 
245 1 0 |a Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure  |b substudy of the RE-LY trial  |c J.D. Douketis, J.S. Healey, M. Brueckmann, J.W. Eikelboom, M.D. Ezekowitz, M. Fraessdorf, H. Noack, J. Oldgren, P. Reilly, A.C. Spyropoulos, L. Wallentin, S.J. Connolly 
264 1 |c 2015: 113/3 (Mar) 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.09.2017 
520 |a In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain.We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for stroke prevention in AF, to assess the potential benefits and risks of bridging. In patients who had a first interruption of dabigatran or warfarin for an elective surgery/procedure, we compared the risk for major bleeding (MB), stroke or systemic embolism (SSE) and any thromboembolism (TE) in patients who were bridged or not bridged during the period of seven days before until 30 days after surgery/procedure. We used multivariable Cox regression to adjust for potential confounders.Bridging was used more during warfarin interruption than dabigatran interruption (27.5 % vs 15.4 %; p< 0.001). With dabigatran interruption, bridged patients had more MB (6.5 % vs 1.8 %, p< 0.001) than those not bridged but bridged and not bridged groups did not differ for any TE (1.2 % vs 0.6 %, p=0.16) and SSE (0.5 % vs 0.3 %, p=0.46). With warfarin interruption, bridged patients had more MB (6.8 % vs 1.6 %, p< 0.001) and any TE (1.8 % vs 0.3 %, p=0.007) than those not bridged but bridged and not bridged groups did not differ for SSE (0.5 % vs 0.2 %, p=0.321). In conclusion, in patients who interrupted dabigatran or warfarin for a surgery/ procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabigatran or warfarin interruption. 
700 1 |a Brückmann, Martina  |d 1970-  |e VerfasserIn  |0 (DE-588)121145069  |0 (DE-627)705257290  |0 (DE-576)292557736  |4 aut 
773 0 8 |i Enthalten in  |t Thrombosis and haemostasis  |d Stuttgart : Thieme, 1976  |g 113(2015), 3, Seite 625-632  |h Online-Ressource  |w (DE-627)302723188  |w (DE-600)1492370-1  |w (DE-576)079877362  |x 2567-689X  |7 nnas  |a Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure substudy of the RE-LY trial 
773 1 8 |g volume:113  |g year:2015  |g number:3  |g pages:625-632  |g extent:8  |a Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure substudy of the RE-LY trial 
856 4 0 |u http://dx.doi.org/10.1160/TH14-04-0305  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://th-schattauer-de.ezproxy.medma.uni-heidelberg.de/contents/archive/issue/2189/manuscript/23790.html  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20170928 
993 |a Article 
994 |a 2015 
998 |g 121145069  |a Brückmann, Martina  |m 121145069:Brückmann, Martina  |d 60000  |e 60000PB121145069  |k 0/60000/  |p 3 
999 |a KXP-PPN1563887479  |e 2981942352 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 28.09.2017"],"title":[{"title_sort":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure","title":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure","subtitle":"substudy of the RE-LY trial"}],"person":[{"display":"Douketis, James D.","family":"Douketis","roleDisplay":"VerfasserIn","given":"James D.","role":"aut"},{"role":"aut","given":"Martina","roleDisplay":"VerfasserIn","family":"Brückmann","display":"Brückmann, Martina"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"id":{"eki":["1563887479"],"doi":["10.1160/TH14-04-0305"]},"physDesc":[{"extent":"8 S."}],"recId":"1563887479","name":{"displayForm":["J.D. Douketis, J.S. Healey, M. Brueckmann, J.W. Eikelboom, M.D. Ezekowitz, M. Fraessdorf, H. Noack, J. Oldgren, P. Reilly, A.C. Spyropoulos, L. Wallentin, S.J. Connolly"]},"relHost":[{"title":[{"title":"Thrombosis and haemostasis","subtitle":"journal of the International Society on Thrombosis and Haemostasis","title_sort":"Thrombosis and haemostasis"}],"note":["Gesehen am 15.06.2018"],"part":{"pages":"625-632","volume":"113","issue":"3","extent":"8","text":"113(2015), 3, Seite 625-632","year":"2015"},"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["302723188"],"issn":["2567-689X"],"zdb":["1492370-1"],"doi":["10.1055/s-00035024"]},"language":["eng"],"pubHistory":["35.1976 -"],"disp":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure substudy of the RE-LY trialThrombosis and haemostasis","recId":"302723188","origin":[{"dateIssuedDisp":"1976-","publisher":"Thieme ; Schattauer","publisherPlace":"Stuttgart ; Stuttgart","dateIssuedKey":"1976"}]}],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"2015: 113/3 (Mar)"}]} 
SRT |a DOUKETISJAPERIOPERAT2015